A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Pitavastatin-D5 Sodium - Request Quote

Picture of Pitavastatin-D5 Sodium

Pitavastatin-D5 Sodium

SZ CAT No:SZ-P023D04
CAS No
NA
Mol.F.
C25H16D5FNO4 : Na
Mol.Wt.
423.5 : 23.0
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Pitavastatin-D5 Sodium is chemically Sodium (R,E)-7-(2-(cyclopropyl-d5)-4-(4-fluorophenyl)quinolin-3-yl)-3-hydroxy-5-oxohept-6-enoate. Pitavastatin-D5 Sodium is supplied with detailed characterization data compliant with regulatory guideline. Pitavastatin-D5 Sodium can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Pitavastatin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Pitavastatin-D5 Sodium

Purchase Pitavastatin-D5 Sodium

Pitavastatin-D5 Sodium suppliers

Pitavastatin-D5 Sodium manufacturers

Pitavastatin-D5 Sodium price

Order Pitavastatin-D5 Sodium

Enquire Pitavastatin-D5 Sodium

Pitavastatin-D5 Sodium cost

Pitavastatin-D5 Sodium Supplier

Pitavastatin-D5 Sodium Distributor

Pitavastatin-D5 Sodium for Method Validation

Pitavastatin Reference Standard

Pitavastatin-D5 Sodium for ANDA Filing

Pitavastatin-D5 Sodium for Forced Degradation Studies

Pitavastatin-D5 Sodium Identification Standards

Pitavastatin-D5 Sodium for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,